Lanvis Use In Pregnancy & Lactation

Thioguanine like other cytotoxic agents is potentially teratogenic.
Fertility: There have been isolated cases where men, who have received combinations of cytotoxic agents including thioguanine, have fathered children with congenital abnormalities.
Pregnancy: The use of thioguanine should be avoided whenever possible during pregnancy, particularly during the first trimester. In any individual case the potential hazard to the foetus must be balanced against the expected benefit to the mother.
As with all cytotoxic chemotherapy, adequate contraceptive precautions should be advised when either partner is receiving thioguanine.
Cholestasis of pregnancy has occasionally been reported in association with azathioprine therapy. Early diagnosis and discontinuation of thioguanine may minimise impact on the foetus. However, a careful assessment of benefit to the mother and impact on the foetus should be performed, if cholestasis of pregnancy is confirmed (see Precautions).
Breastfeeding: There are no reports documenting the presence of thioguanine or its metabolites in maternal milk. It is suggested that mothers receiving thioguanine should not breast feed.